NZ595174A - Prebiotic galacto oligosaccharides used to stimulate growth or colonisation of beneficial bifidobacterium bacteria in gut - Google Patents

Prebiotic galacto oligosaccharides used to stimulate growth or colonisation of beneficial bifidobacterium bacteria in gut

Info

Publication number
NZ595174A
NZ595174A NZ595174A NZ59517410A NZ595174A NZ 595174 A NZ595174 A NZ 595174A NZ 595174 A NZ595174 A NZ 595174A NZ 59517410 A NZ59517410 A NZ 59517410A NZ 595174 A NZ595174 A NZ 595174A
Authority
NZ
New Zealand
Prior art keywords
colonisation
gut
stimulate growth
bifidobacterium bacteria
oligosaccharides used
Prior art date
Application number
NZ595174A
Other languages
English (en)
Inventor
Mariana Barboza
J German
Original Assignee
Univ California
Dsm Food Specialties Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42728831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ595174(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California, Dsm Food Specialties Usa Inc filed Critical Univ California
Publication of NZ595174A publication Critical patent/NZ595174A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01108—Lactase (3.2.1.108)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pediatric Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ595174A 2009-03-13 2010-03-12 Prebiotic galacto oligosaccharides used to stimulate growth or colonisation of beneficial bifidobacterium bacteria in gut NZ595174A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16008809P 2009-03-13 2009-03-13
PCT/US2010/027206 WO2010105207A1 (en) 2009-03-13 2010-03-12 Prebiotic oligosaccharides

Publications (1)

Publication Number Publication Date
NZ595174A true NZ595174A (en) 2013-04-26

Family

ID=42728831

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595174A NZ595174A (en) 2009-03-13 2010-03-12 Prebiotic galacto oligosaccharides used to stimulate growth or colonisation of beneficial bifidobacterium bacteria in gut

Country Status (7)

Country Link
US (3) US8425930B2 (enExample)
EP (1) EP2405918B2 (enExample)
JP (1) JP2012520325A (enExample)
AU (1) AU2010223965A1 (enExample)
CA (1) CA2760999A1 (enExample)
NZ (1) NZ595174A (enExample)
WO (1) WO2010105207A1 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
JP5618544B2 (ja) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN102316897B (zh) 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
WO2010098822A1 (en) 2009-02-24 2010-09-02 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
EP3202406A1 (en) 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
SG10202110501RA (en) 2010-12-31 2021-11-29 Abbott Lab Methods For Decreasing The Incidence Of Necrotizing Enterocolitis In Infants, Toddlers, Or Children Using Human Milk Oligosaccharides
WO2012092159A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
JP6129821B2 (ja) 2011-05-13 2017-05-17 グリコシン リミテッド ライアビリティー カンパニー プレバイオティクスとしての、精製された２’−フコシルラクトース、３−フコシルラクトース、およびラクトジフコテトラオースの使用
BR112014001472A2 (pt) * 2011-07-22 2017-02-21 Abbott Lab galactooligossacarídeos para prevenir lesões e / ou promover a cicatrização do trato gastrointestinal
US9463169B2 (en) 2011-08-17 2016-10-11 Microbiome Therapeutics, Llc Human gastrointestinal microbiome modulating food supplement for improving blood glucose regulation
BR112014004772A2 (pt) 2011-08-29 2017-03-21 Abbott Lab oligossacarídeos do leite humano para evitar danos e/ou promover a cura do trato gastrointestinal
US20150087616A1 (en) * 2011-11-30 2015-03-26 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
BR112015020977A2 (pt) 2013-03-08 2017-07-18 Axiom Foods Inc suplemento de proteína de arroz e métodos de uso do mesmo
US9820504B2 (en) 2013-03-08 2017-11-21 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
WO2014145276A1 (en) 2013-03-15 2014-09-18 Cargill, Incorporated Carbohydrate compositions
GB201305708D0 (en) 2013-03-28 2013-05-15 Clasado Inc Novel use
EP3542633A1 (en) * 2014-03-06 2019-09-25 Arla Foods amba Lactose-reduced milk products containing galacto-oligosaccharides and limited amount of monosaccharides and a method of production
EP3164145A4 (en) 2014-07-01 2018-01-17 Probi Usa, Inc. Bi-layer dual release probiotic tablets
US10752705B2 (en) 2014-07-09 2020-08-25 Cadena Bio, Inc. Oligosaccharide compositions and methods for producing thereof
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
CN115350200A (zh) 2014-12-08 2022-11-18 格礼卡姆股份公司 用于治疗代谢障碍的合成组合物
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
EP3229595B1 (en) 2014-12-12 2021-02-03 The Regents of the University of California Reduction of milk glycans and their degradation products in the neonate gut
EP4205553A1 (en) 2015-01-26 2023-07-05 DSM Nutritional Products, LLC Oligosaccharide compositions for use animal feed and methods of producing thereof
ES2857557T3 (es) 2015-01-26 2021-09-29 Kaleido Biosciences Inc Compuestos terapéuticos de glicano y métodos relacionados de los mismos
SG11201708635QA (en) * 2015-04-23 2017-11-29 Kaleido Biosciences Inc Microbiome regulators and related uses thereof
CA2983236A1 (en) 2015-04-23 2016-10-27 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
EP3349763B1 (en) 2015-09-14 2021-08-11 Glycom A/S Composition for use in microbiota modulation
WO2019119102A1 (en) * 2017-12-22 2019-06-27 Vitalus Nutrition Inc. Method for producing galactooligosaccharides from lactose
US10337042B2 (en) 2016-01-12 2019-07-02 Vitalus Nutrition Inc. Method for producing galactooligosaccharides from lactose
CA2992497C (en) * 2016-01-12 2020-12-22 Vitalus Nutrition Inc. Method for producing galactooligosaccharides from lactose
EP3419630A4 (en) * 2016-02-24 2019-11-06 Glycom A/S SYNTHETIC COMPOSITION FOR MICROBIOTA MODULATION
BR112018068261A2 (pt) 2016-03-11 2019-01-15 Evolve Biosystems Inc microorganismo comensal transitório para melhorar a saúde do intestino
WO2017190755A1 (en) * 2016-05-05 2017-11-09 Glycom A/S Composition comprising hmos for use in the treatment of mast cell mediated visceral hypersensitivity and/or pain
AU2017290900A1 (en) * 2016-07-01 2019-01-17 Infinant Health, Inc Method for facilitating maturation of the mammalian immune system
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
WO2018048305A1 (en) 2016-09-12 2018-03-15 Rijksuniversiteit Groningen Prebiotic branched galacto-oligosaccharides (gos)
CN109843073A (zh) * 2016-09-19 2019-06-04 普罗莱克塔生物科学公司 经纯化的人乳低聚糖组合物
WO2018065104A1 (en) * 2016-10-07 2018-04-12 Boehringer Ingelheim Vetmedica Gmbh Analysis system and method for testing a sample
EP3634155A4 (en) 2017-05-12 2021-02-17 Axiom Foods Inc. RICE PRODUCTS AND SYSTEMS AND PROCESSES FOR THEIR PRODUCTION
WO2019025637A1 (en) * 2017-08-04 2019-02-07 Nestec S.A. PRECONDITIONED PROBIOTIC BACTERIA IN A GOS-CONTAINING ENVIRONMENT AND USE THEREOF
EP3703705B1 (en) 2017-11-03 2024-05-15 DSM Nutritional Products, LLC Glucose-containing glycan preparations for use in the treatment of hyperammonaemia
KR102032799B1 (ko) 2017-11-16 2019-10-17 고려대학교 산학협력단 해조류 유래 아가로트리오스의 제조방법 및 프리바이오틱로서의 용도
JPWO2019117212A1 (ja) * 2017-12-12 2020-12-03 森永乳業株式会社 ビフィドバクテリウム属細菌を有効成分とする組成物
US11304966B2 (en) 2017-12-22 2022-04-19 Glycom A/S Composition comprising HMOs for preventing or reducing nociception
EP3801557A4 (en) 2018-05-30 2022-03-09 Evolve Biosystems Inc. COMPOSITIONS AND METHOD OF USE FOR BIFIDOBACTERIUM LONGUM SUBSP. COMPETENT FOR H5
EP3598901A1 (de) * 2018-07-23 2020-01-29 optiferm GmbH Beta-galactosidase aus l. bulgaricus zur synthese von galactooligosacchariden in molke
KR20210058854A (ko) * 2018-09-06 2021-05-24 프리슬랜드캄피나 네덜란드 비.브이. 비피더스 활성 저알레르기성 gos 조성물 및 락토바실러스 델브루에키 ssp 불가리쿠스의 균주로부터의 베타-갈락토시다제를 수반하는 이의 제공 방법
EP3646739A1 (en) 2018-11-01 2020-05-06 N.V. Nutricia Nutritional composition comprising urea and non-digestible oligosaccharides
JP7502296B2 (ja) * 2018-12-03 2024-06-18 デュポン ニュートリション バイオサイエンシス エーピーエス 高ｇｏｓ繊維レベル及び低ラクトースレベルを提供するためのラクターゼの使用
CN109880813B (zh) * 2019-03-20 2022-06-07 安徽大学 一种具有低聚半乳糖合成能力的β-葡萄糖苷酶及其表达菌株和应用
EP3994163A1 (en) * 2019-07-01 2022-05-11 Société des Produits Nestlé S.A. Serpin production
MX2022002949A (es) 2019-09-24 2022-04-06 Prolacta Bioscience Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias e inmunes.
CN111849940B (zh) * 2020-07-28 2022-03-25 量子高科(广东)生物有限公司 一种β-半乳糖苷酶的制备方法及其应用
JP6978621B1 (ja) * 2021-03-12 2021-12-08 森永乳業株式会社 組成物
EP4101301A1 (de) * 2021-06-08 2022-12-14 DMK Deutsches Milchkontor GmbH Verfahren zur herstellung von galactooligosacchariden
US12156859B2 (en) 2021-12-20 2024-12-03 Tainnovation Inc. Methods of and compositions for treating obesity, obesity-related diseases or cancers using a N6-methyllysine/l-lysine mixture
WO2024112684A1 (en) * 2022-11-22 2024-05-30 Fairlife, Llc Process for producing galactooligosaccharides
GB2628547A (en) 2023-03-27 2024-10-02 Univ Newcastle Probiotic and postbiotic compositions, products and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3072670B2 (ja) * 1992-02-28 2000-07-31 味の素株式会社 ガラクトオリゴ糖の製造方法
DE19701382A1 (de) * 1997-01-16 1998-07-23 Nutricia Nv Kohlenhydratmischung
AU761477B2 (en) * 1998-06-17 2003-06-05 New Zealand Dairy Board Bioactive whey protein hydrolysate
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
FR2844453B1 (fr) † 2002-09-13 2006-05-19 Agronomique Inst Nat Rech Utilisation de pre-biotiques pour la prevention de l'installation du diabete de type ii
MXPA05003597A (es) * 2002-10-11 2005-06-03 Wyeth Corp Formulaciones nutricionales que contienen sustancias simbioticas.
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
GB0308104D0 (en) * 2003-04-08 2003-05-14 Novartis Nutrition Ag Organic compounds
EP1644482B2 (en) * 2003-06-30 2014-10-01 Clasado Inc. Novel galactooligosaccharide composition and the preparation thereof
US20060115465A1 (en) * 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
US20070141678A1 (en) * 2005-12-19 2007-06-21 The Procter & Gamble Company Processes for purifying oligosaccharides
EP1887017A1 (en) 2006-08-09 2008-02-13 Friesland Brands B.V. Prebiotic carbohydrate
ATE524190T1 (de) † 2006-10-02 2011-09-15 Friesland Brands Bv Hemmung von cholera-toxinen durch galatooligosacchariden (gos)
WO2008153377A1 (en) † 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide

Also Published As

Publication number Publication date
EP2405918A1 (en) 2012-01-18
JP2012520325A (ja) 2012-09-06
EP2405918A4 (en) 2013-01-09
US8425930B2 (en) 2013-04-23
US20170000811A1 (en) 2017-01-05
US20140037785A1 (en) 2014-02-06
CA2760999A1 (en) 2010-09-16
AU2010223965A1 (en) 2011-10-06
EP2405918B1 (en) 2014-10-22
WO2010105207A1 (en) 2010-09-16
EP2405918B2 (en) 2020-09-02
US20100254949A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
NZ595174A (en) Prebiotic galacto oligosaccharides used to stimulate growth or colonisation of beneficial bifidobacterium bacteria in gut
PH12015501309A1 (en) Human milk oligosaccharides to ameliorate symptoms of stress
MY161034A (en) Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
WO2014018596A3 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
TN2011000416A1 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
RU2008147883A (ru) Применение молочнокислых бактерий для уменьшения детской колики
WO2012112777A3 (en) Biosynthesis of human milk oligosaccharides in engineered bacteria
JP2016529309A5 (enExample)
UA100551C2 (en) Synbiotic mixture
SG10201901259RA (en) Prebiotic formulations and methods of use
RU2013128570A (ru) Олигосахаридная композиция для лечения острых инфекций дыхательных путей
NZ613180A (en) Methods of using human milk oligosaccharides for improving airway respiratory health
EP4233545A3 (en) Synergistic bacterial compositions and methods of production and use thereof
AR067906A1 (es) Lactobacillus rhamnosus y control del peso
NZ612455A (en) Human milk oligosaccharides to promote growth of beneficial bacteria
IN2012DN03632A (enExample)
RU2013128594A (ru) Композиция для применения с целью предупреждения и/или лечения состояний кожи и заболеваний кожи
MX2012013465A (es) Lactamas sustituidas con piperidinilo como moduladores de gpr119.
NZ602249A (en) Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders
NZ581390A (en) Prebiotics comprising an oligosaccharide, sialyloligosaccharide and free sialic acid
AR078485A1 (es) Bifidobacterium longum atcc baa-999 (bl999) y control de peso
BR112013000921A2 (pt) tratamento de infecções pulmonares pela administração de tobramicina por aerolização
GB2549400A (en) Creped prebiotic tissue
UA107711C2 (en) Use of lactobacilli inhibiting gas producing coliform bacteria isolated from infants affected by colic
MX363923B (es) Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 MAR 2017 BY IN-LEGAL LIMITED

Effective date: 20140901

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2024 BY COMPUTER PACKAGES INC

Effective date: 20230217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2026 BY COMPUTER PACKAGES INC

Effective date: 20250217